<code id='79BB5397BC'></code><style id='79BB5397BC'></style>
    • <acronym id='79BB5397BC'></acronym>
      <center id='79BB5397BC'><center id='79BB5397BC'><tfoot id='79BB5397BC'></tfoot></center><abbr id='79BB5397BC'><dir id='79BB5397BC'><tfoot id='79BB5397BC'></tfoot><noframes id='79BB5397BC'>

    • <optgroup id='79BB5397BC'><strike id='79BB5397BC'><sup id='79BB5397BC'></sup></strike><code id='79BB5397BC'></code></optgroup>
        1. <b id='79BB5397BC'><label id='79BB5397BC'><select id='79BB5397BC'><dt id='79BB5397BC'><span id='79BB5397BC'></span></dt></select></label></b><u id='79BB5397BC'></u>
          <i id='79BB5397BC'><strike id='79BB5397BC'><tt id='79BB5397BC'><pre id='79BB5397BC'></pre></tt></strike></i>

          hotspot

          hotspot

          author:leisure time    Page View:6296
          The Federal Trade Commission office glows softly inside, contrasting with the darkness outside — coverage from STAT
          Adobe

          Over the past two decades, hundreds of hospital mergers have escaped federal antitrust scrutiny and led to both higher prices and less competition, a new study shows.

          But the study’s authors, and other researchers, believe the Federal Trade Commission’s hands often are tied. The agency simply doesn’t have enough money or people to crack down on all anticompetitive hospital deals, and some state laws shield hospital mergers from federal review completely.

          advertisement

          “The resources available are just not commensurate with what the agency needs,” said Zack Cooper, an associate professor of health policy and economics at Yale University and one of the co-authors of the study. “This isn’t a story of the FTC not knowing what to do. I actually think they really know, very clearly, what to do. It’s a lack of resources, person power, and potentially willingness to do it.”

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Apple is now the first public company to be valued at $3 trillion
          Apple is now the first public company to be valued at $3 trillion

          6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

          read more
          Group behind ProMed defends move to subscription
          Group behind ProMed defends move to subscription

          ProMEDmapScreengrabviaProMEDTheorganizationthatrunsProMed,anearlywarningsystemondiseaseoutbreaks,def

          read more
          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more

          Alnylam reports growth in sales of rare disease treatments

          KristofferTripplaar/SipaUSA/APAlnylamPharmaceuticalssaidThursdaythatsalesofitstreatmentsforraredisea